🔬Help Us Better Support Scientists Worldwide!💜
🔗Take our Global Survey: medchemexpress.com/global-ma…
🌎Join the MedChemExpress Research Community by sharing your information. Stay connected with us to access the latest research resources and discover how MCE’s products and services can support your scientific journey.
Thank you for being part of the scientific community driving innovation forward. 🧪
#LifeScience#ScientificResearch#Biotechnology#DrugDiscovery#ResearchCommunity
🚨FDA Approval Update | First Drug Approved for Primary Membranous Nephropathy
The FDA approved Gazyva (#obinutuzumab) for adults with primary membranous nephropathy (pMN) who are at risk of disease progression, marking the first FDA-approved drug specifically for this rare autoimmune kidney disease.
Phase 3 MAJESTY trial, involving 142 adults with pMN:
🔹Complete remission of #proteinuria at Week 104: 36% with obinutuzumab vs. 6% with tacrolimus.
🧪MedChemExpress offers biologically-validated obinutuzumab for research-use only: medchemexpress.com/Obinutuzu…#FDAApproval#Gazyva#MembranousNephropathy#BCells#CD20#Immunology#Nephrology
🧬Research Spotlight | Beyond the Payload: How Are Drug Delivery Systems Evolving?
A new review in Signal Transduction and Targeted Therapy explores the latest advances in drug delivery systems (DDS), highlighting how delivery technologies are becoming critical determinants of therapeutic efficacy and clinical translation.
The review examines four major categories of delivery technologies:
🔹Nanocarrier-based systems: Lipid nanoparticles (#LNPs), polymeric nanoparticles, and inorganic nanoparticles.
🔹Targeted molecular conjugates: Antibody-drug conjugates (ADCs), peptide-drug conjugates, and other targeted platforms.
🔹Biological delivery systems: Viral and non-viral vectors, cell-mediated delivery, engineered bacteria, and extracellular vesicles.
🔹Emerging platforms: Hydrogels, device-assisted delivery, and hybrid delivery systems.
The authors highlight several priorities for next-generation DDS development:
💡Improving tissue targeting and intracellular delivery, particularly endosomal escape.
💡Overcoming biological barriers such as the blood–brain barrier (BBB) and tumor microenvironment.
💡Integrating AI-enabled design and programmable delivery architectures.
💡Addressing safety, manufacturing scalability, and reproducibility to accelerate clinical translation.
Explore Related MCE Products for Drug Delivery Research:
⭐LNP & Lipids: medchemexpress.com/search.ht…
⭐Oligonucleotides: medchemexpress.com/oligonucl…
⭐ADC: medchemexpress.com/Pathways/…#DrugDelivery#Nanomedicine#LipidNanoparticles#ADCs#DrugDiscovery#Biotechnology#RNAResearch
I just published Struggling with Protein Localization? Start with These 12 Organelle Markers!
🔹 MCE validation images (IF / IHC / WB)
🔹 Antibody selection tips
🔹 Common experimental pitfalls
💡 A handy reference for subcellular identification and protein localization studies!
medium.com/@medchemexpress_l…
🚨FDA Approval Update | Giredestrant + Everolimus Approved for ESR1-Mutated Breast Cancer
The FDA approved #giredestrant (Wilserdly, Roche) in combination with #everolimus for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer following progression on or after endocrine-based therapy.
🔬Phase 3 evERA Breast Cancer trial:
🔸Median PFS: 10 months with giredestrant + everolimus vs. 5.5 months with endocrine therapy + everolimus.
🔸Risk of disease progression or death: Reduced by 62% (HR 0.38) compared with the control.
🔸ORR: 27% vs. 14%, respectively.
Giredestrant is an oral estrogen receptor antagonist, offering a targeted endocrine approach for ESR1-mutated breast cancer. The approval also highlights the importance of molecular testing in identifying patients who may benefit from specific treatment strategies.
🧪MedChemExpress offers 6100+ breast cancer-related research tools, across inhibitors & agonists, natural products, lipids, peptides, reference standards, etc: medchemexpress.com/disease-a…#FDAApproval#BreastCancer#Giredestrant#ESR1#EstrogenReceptor#Oncology#CancerResearch#MedChemExpress
🧬 Beyond Protein Degradation: 10 #CIP Strategies
Chemically Induced Proximity (#CIP) is expanding targeted protein modulation beyond degradation—reshaping protein interactions, localization, and cellular functions.
🔬 ① Targeted Protein Degradation: #PROTACs, #LYTACs, #AUTACs, #ATTECs, #SNIPERs & Molecular Glue Degraders.
🔬 ② Beyond Degradation: #RIPTACs, #TCIPs, #TRAMs & #DALTACs.
While PROTACs and molecular glue degraders have FDA-approved examples, other approaches are advancing through preclinical and clinical development.
🧪 Explore MCE's E3 ligase ligands, screening libraries, research services & compound customization.
🔗 medchemexpress.com/Pathways/…
🚨FDA Approval Update | Pimicotinib Approved for Tenosynovial Giant Cell Tumor (TGCT)
The FDA approved #pimicotinib (Pimjetmi), a kinase inhibitor, for adults with symptomatic tenosynovial giant cell tumor (TGCT) when surgical resection may cause worsening functional limitations or severe morbidity.
Phase 3 MANEUVER trial:
📊Overall response rate (ORR): 56% with pimicotinib vs. 3.2% with placebo at Week 25.
📊Durability of response: 91% of responders maintained responses for at least 6 months, while 77% maintained responses for at least 12 months.
📊Patients also experienced improvements in joint range of motion, pain, and physical functioning.
💡Pimicotinib represents a new targeted approach to TGCT, highlighting the potential of #kinase inhibition for managing tumors where surgery may result in substantial functional impairment.
MedChemExpress offers 4700+ kinase-related inhibitors & agonists: medchemexpress.com/search.ht…#FDAApproval#TGCT#CancerResearch#KinaseInhibitors#ClinicalTrials
🧬Research Spotlight | Beyond Kinase Inhibition: What’s Next for Kinase Drug Discovery?
A new review in Nature Reviews Drug Discovery explores how the field is evolving, highlighting emerging kinase targets, novel drug modalities, and opportunities beyond oncology.
⭐Targeted protein degradation: PROTACs and molecular glues offer new ways to eliminate kinase proteins, including their non-catalytic functions.
⭐New therapeutic modalities: Macrocyclic inhibitors, antibody–drug conjugates (#ADCs), and cell-based approaches are broadening the strategies available for targeting kinases.
⭐Expanding target landscape: Around half of the canonical human protein kinases now have at least one clinical-stage agent.
⭐New disease indications: Kinase-targeting strategies are increasingly being explored in immunological, neurological, metabolic, and other non-oncology conditions.
As kinase research moves beyond traditional inhibition, understanding kinase activity, regulation, and biological functions is becoming increasingly important.
🧪Discover kinase research tools from MedChemExpress, including a broad selection of kinase inhibitors and related research reagents, to support your studies of kinase activity and signaling pathways.
Explore MCE's Kinase Screening Service to support your kinase research:
🔸400+ kinases: Coverage across AGC, CAMK, CMGC, CK1, STE, TK, and TKL families, including common mutants.
🔸Flexible screening panels: Characteristic TK and CDK profiles, 60-, 207-, and 302-kinase panels, plus customized options.
🔸Multiple detection methods: TR-FRET, fluorescence-based assays, Z'-LYTE, and binding assays.
🔸Rapid turnaround: Results available in as little as one week.
🔸Functional assessment: Accurate evaluation of kinase activity.
medchemexpress.com/kinase-sc…#Kinase#KinaseInhibitors#TargetedProteinDegradation#PROTAC#MolecularGlue#DrugDiscovery#MolecularBiology
🧬Research Spotlight | How do platelets influence sex-specific anti-tumor immunity in glioblastoma?
A new study published in Cancer Cell identifies platelet protease-activated receptor 4 (#PAR4) signaling as a key regulator of sex-specific immune responses in #glioblastoma (GBM).
🔸GBM patients exhibit increased platelet reactivity associated with PAR4 signaling.
🔸PAR4-activated platelets suppress CD8⁺ T-cell activity, potentially weakening anti-tumor immunity.
🔸In preclinical models, pharmacological or genetic PAR4 inhibition improved survival in female mice.
🔸This effect was estrogen-dependent and associated with enhanced CD8⁺ T-cell infiltration and function in the tumor microenvironment.
🔸Mechanistically, PAR4 inhibition enhanced CD8⁺ T-cell signaling through an interaction involving estrogen receptor β (ERβ).
🧪Explore PAR4-related research tools from MedChemExpress: medchemexpress.com/Targets/P…
🧪Glioblastoma-related research tools: medchemexpress.com/disease-a…#CancerResearch#TumorMicroenvironment#Platelets#CD8TCells#Immunology
🧬FDA Safety Update | The #FDA is requiring updated safety warnings for all glucagon-like peptide-1 (GLP-1) receptor agonist medications following an evaluation of a potential association with non-arteritic anterior ischemic optic neuropathy (NAION), a rare eye condition that can cause sudden, potentially permanent vision loss.
🧐What is NAION?
NAION occurs when blood flow to the optic nerve is reduced, potentially resulting in sudden, painless vision loss, usually in one eye.
📊Key findings from the FDA review:
🔹An analysis of 126 clinical trials involving 134,253 participants found 6.4 NAION cases per 100,000 person-years among GLP-1 RA users, compared with 3.8 in comparator groups.
🔹The warning applies across the GLP-1 RA class, including semaglutide, liraglutide, dulaglutide, and other medications with GLP-1 receptor agonist activity.
#GLP1#Semaglutide#NAION#DrugSafety#FDA#Pharmacovigilance#MedicalResearch
🏆MedChemExpress Wins the 2026 Bioz Stars Award in the #Proteins Category!
We’re proud to receive the 2026 Bioz Stars Award, recognizing the quality and breadth of MedChemExpress (MCE)'s recombinant protein portfolio and its contribution to scientific research.
🧬14,000+ Recombinant Proteins | Comprehensive Research Coverage
MCE covers a broad range of research needs, from cytokines and growth factors to immune checkpoint proteins, kinases, enzymes, viral proteins, and GMP-grade proteins. Multiple species and applications support research spanning cell culture, mechanism studies, protein interactions, and drug discovery.
🔬Scientific Data | Quality Backed by Evidence
MCE recombinant proteins are supported by comprehensive characterization data, including SDS-PAGE, HPLC, SEC-MALS, Western Blot, ELISA, SPR, BLI, and cell-based activity assays. With catalog products offering over 95% purity, low endotoxin levels, and verified biological activity, MCE emphasizes quality and performance backed by experimental data.
✨Five Expression Platforms | Advanced Custom Solutions
Leveraging five expression platforms: E. coli, E. coli cell-free, yeast, insect cells, and mammalian cells, MCE supports diverse protein production needs. Advanced technologies for membrane protein preparation, multiple tag options, and customized purification solutions further expand research possibilities.
⭐GMP-Grade & Animal Component-Free | Ready for Evolving Research Needs
With traceable GMP-grade proteins and animal component-free recombinant proteins, MCE provides solutions for organoid, stem cell, and cell therapy research, supporting the growing demand for animal-origin-free and chemically defined research materials.
MCE remains committed to delivering high-quality recombinant proteins and comprehensive technical solutions to empower scientific discovery.
🔗Explore MCE Recombinant Proteins: medchemexpress.com/recombina…#BiozStarsAwards#RecombinantProteins#GMP#LifeScience#ScientificResearch
🧬FDA Approval Update | First Factor XIa Inhibitor Approved for Secondary Stroke Prevention
The #FDA has approved Sunharbo (asundexian), developed by Bayer, in combination with antiplatelet therapy to reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke or high-risk transient ischemic attack (TIA).
Asundexian is an oral, once-daily selective FXIa inhibitor designed to reduce pathological blood clot formation by inhibiting thrombin generation amplification, while potentially preserving normal hemostasis.
📊OCEANIC-STROKE Phase 3 trial involving 12327 participants:
🔹Reduced the risk of ischemic stroke by 26% compared with placebo.
🔹Evaluated asundexian in combination with antiplatelet therapy.
💡Factor XIa inhibition represents a new approach to anticoagulation research, highlighting the potential of targeting pathological thrombosis while preserving physiological hemostasis.
🔗Read more: fda.gov/news-events/press-an…
🧪Explore research-use #Asundexian from MedChemExpress: medchemexpress.com/asundexia…#FDAApproval#FactorXIa#IschemicStroke#Anticoagulation#DrugDiscovery
🧬Research Spotlight | Can molecular glue degraders unlock new targets in autoimmune diseases?
Hinova Pharmaceuticals' investigational drug HP570, an oral #VAV1 molecular glue degrader, received FDA IND clearance for rheumatoid arthritis (RA) on November 4, 2026. The following day, Hinova signed an exclusive licensing agreement with Evommune, granting worldwide rights outside Greater China.
Why VAV1?
🔸VAV1 is a key signaling protein involved in T-cell and B-cell activation.
🔸It plays an important role in T-cell receptor (TCR) and B-cell receptor (BCR) signaling.
🔸Targeting VAV1 for degradation may offer a strategy to modulate immune signaling in autoimmune diseases.
💡HP570 is designed to induce VAV1 degradation through a molecular glue mechanism, highlighting the potential of targeted protein degradation beyond conventional enzyme inhibition.
🧪Explore research-use molecular glue degraders from MedChemExpress: medchemexpress.com/Targets/m…
🔗Read more: flcube.com/hinova-licenses-o…#MolecularGlue#TargetedProteinDegradation#AutoimmuneDisease#RheumatoidArthritis#DrugDiscovery
🏆MedChemExpress Wins the 2026 Bioz Stars Award in the #Peptides Category!
We’re proud to receive the 2026 Bioz Stars Award in recognition of MedChemExpress (MCE)'s peptide portfolio and its contribution to scientific research.
🧬10,000+ Peptides | Broad Research Applications
With 10,000+ in-stock peptides covering major research areas, MCE provides diverse tools for neuroscience, oncology, apoptosis, metabolism, inflammation, immunology, and more.
🔬From Catalog to Custom | Comprehensive Peptide Solutions
Beyond our extensive catalog, MCE offers customized solutions for linear and cyclic peptides, modified peptides, peptide libraries, recombinant peptides, and peptide-drug conjugates (PDCs), with flexible production scales from mg to kg.
✨Advanced Synthesis | Quality You Can Trust
Supported by advanced synthesis technologies, 300+ modification options, and rigorous quality control, MCE ensures reliable peptide purity and structural accuracy. HPLC and MS analysis, together with functional validation, support confidence in peptide research.
Thank you to the scientific community for your continued trust and support!
🧪MedChemExpress is committed to providing high-quality peptide tools for scientific research and drug discovery: ow.ly/JZLG5104o09#PeptideSynthesis#DrugDiscovery#ResearchTools
🏆 MedChemExpress Wins the 2026 Bioz Stars Award in the #Inhibitors Category!
We’re honored to receive this recognition, highlighting our continued commitment to delivering high-quality research tools and supporting scientific discovery.
Powered by Bioz’s patented AI technology and analysis of 35 million scientific publications, the Bioz Stars Awards recognize the impact of research products in scientific literature. In 2026, MCE inhibitors have been cited in 12,000+ scientific publications!
At MedChemExpress, we continue to strengthen our inhibitor portfolio and research support capabilities:
🧪150,000+ Specific Inhibitors & Agonists
Covering 1,500+ targets and 400+ disease areas, including key research areas such as #JAK, #STING, PD-1, #KRAS, and #ferroptosis.
📊Comprehensive Research Support
Featuring 150,000+ solubility data points and 1 million+ gene and pathway data points to support informed research decisions.
🔬Comprehensive Quality Control
Backed by four biological validation platforms covering #molecular, #protein, #cellular, and in vivo assays. Each batch comes with a complete Certificate of Analysis (COA), supporting consistent product quality and reproducible research.
🌍Global R&D & Distribution Network
Backed by extensive custom synthesis capabilities and professional technical support.
This recognition is a testament to the trust and support of our customers and the global research community. We remain committed to bringing researchers more high-quality products and innovative solutions, empowering scientific discovery around the world. ow.ly/A8b05104nIw#BiozStarsAward#Inhibitors#Agonists#LifeScience#ResearchTools#ScientificResearch#AI#MedChemExpress